Search Within

Gunjan Lalitchandra Shah

Formats
  1. Meeting Abstract (272)
  2. Journal Article (124)
  3. Research Letter (13)
  4. Review (6)
  5. Correspondence (2)
  6. Guidelines (1)
Groups
  1. Bone Marrow Transplant (418)
  2. Center for Hematologic Malignancies (418)
  3. Department of Medicine (418)
  4. Hematologic Malignancies, Division of (418)
  5. Survivorship Research (418)
  6. CTCR Scholars (321)

More Groups

People
  1. Sergio Giralt (297)
  2. Michael Scordo (277)
  3. Miguel-Angel Perales (192)
  4. Sean Devlin (177)
  5. Parastoo Dahi (155)
  6. Heather Landau (154)

More People

Years
  1. 2025 (12)
  2. 2024 (54)
  3. 2023 (85)
  4. 2022 (55)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Blood (137)
  2. Biology of Blood and Marrow Transplantation (73)
  3. Clinical Lymphoma, Myeloma and Leukemia (39)
  4. Transplantation and Cellular Therapy (23)
  5. Blood Advances (20)
  6. Bone Marrow Transplantation (19)

More Publications

Publishers
  1. American Society of Hematology (157)
  2. Elsevier Inc. (142)
  3. Nature Publishing Group (31)
  4. American Society of Clinical Oncology (14)
  5. Taylor & Francis Group (9)
  6. Wiley Blackwell (7)

More Publishers

Results (418)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • EASIX and modified-EASIX are early predictors of severe cytokine release syndrome and neurotoxicity in patients treated with chimeric antigen receptor T cells
    Meeting Abstract

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J.; Maloy, M. A.; Silverberg, M. L.; Batlevi, Y.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; Devlin, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact and safety of chimeric antigen receptor T cell therapy in vulnerable older patients with relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, J. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Hematological count recovery in patients undergoing treatment with chimeric antigen receptor T cells (CAR T)
    Meeting Abstract

    Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Maloy, M. A.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Early experience using radiotherapy as a salvage treatment for relapsed or refractory non-Hodgkin lymphomas following CD19 chimeric antigen receptor modified T-cell therapy
    Meeting Abstract

    Imber, B.; Palomba, M. L.; DeSelm, C.; Dahi, P. B.; Sauter, C. S.; Scordo, M.; Batlevi, C. L.; Park, J. H.; Shah, G. L.; Giralt, S. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
    Meeting Abstract

    Imber, B.; Palomba, M. L.; DeSelm, C.; Batlevi, C. L.; Dahi, P. B.; Giralt, S. A.; Noy, A.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save